Hepatorenal Dysfunctions Among Workers Exposed To Petroleum Products

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess the liver and renal functions of individuals who are occupationally exposed to petroleum products.

Detailed Description
-----------------
Certain peoples have a greater risk of exposure to gasoline vapors; these include filling-station workers, service station attendants, drivers of gasoline trucks and refinery workers.Benzene is metabolized in the liver by cytochrome P450 (CYP) 2E1 to benzene oxide. The metabolites undergo further metabolism through oxidation, dehydrogenation or conjugation with sulfate or glucuronic acid . Activation of benzene and its reactive metabolites leads to continuous production of reactive oxygen species (ROS), which leads to lipid peroxidation and damages DNA, RNA, leading to genetic modification and alterations in the functions of important enzymes (i.e. liver) and proteins . Volatile organic compounds such as gasoline and other fuels are associated with a wide variety of deleterious health effects including liver and kidney diseases. A comparative cross sectional study was conducted from January 2018 to April 2018 at Mekelle city, Tigray region, Northern Ethiopia among gasoline station workers and reporting that the mean level of ALT, AST, Urea, creatinine, and uric acid was significantly higher among gasoline stations workers when compared to control study participants and there was also a significant increase in ALT, AST, Urea, creatinine and uric acid among gasoline stations with increase duration of exposure .

Official Title
-----------------
Hepatorenal Dysfunctions Among Workers Exposed To Petroleum Products

Conditions
-----------------
Petroleum Product Toxicity

Intervention / Treatment
-----------------
* Diagnostic Test: Liver function tests.
* Diagnostic Test: kidney function tests


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: for exposed group: Apparently health workers who exposed for petroleum products in The Petroleum Pipelines Company in assiut will be included in the study Exclusion Criteria: for exposed and Comparison groups history of hepatic and renal health problem history of taking medications affecting liver and renal function tests

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| exposed group<br>workers in The Petroleum Pipelines Company who are occupationally exposed to petroleum products will be included in the study. | Diagnostic Test: Liver function tests.<br>* serum alanine amino transferase (ALT), aspartate amino transferase (AST), albumin (ALB), alkaline Phosphatase (ALP), total bilirubin.<br>Diagnostic Test: kidney function tests<br>* creatinine , urea and serum uric acid will be analysed in the serum.<br>|
| Comparison group (control group)<br>healthy administrative workers in assiut university | Diagnostic Test: Liver function tests.<br>* serum alanine amino transferase (ALT), aspartate amino transferase (AST), albumin (ALB), alkaline Phosphatase (ALP), total bilirubin.<br>Diagnostic Test: kidney function tests<br>* creatinine , urea and serum uric acid will be analysed in the serum.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measurement of serum alanine amino transferase (ALT) in study participants. | Number of participants with abnormal findings in serum alanine amino transferase (ALT) will be reported. | 6 months | 
| measurement of serum aspartate amino transferase (AST) in study participants. | Number of participants with abnormal findings in serum aspartate amino transferase (AST) will be reported. | 6 months | 
| measurement of serum total bilirubin in study participants. | Number of participants with abnormal findings in serum total bilirubin will be reported. | 6 months | 
| measurement of serum albumin (ALB) in study participants. | Number of participants with abnormal findings in serum albumin (ALB) will be reported. | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of serum urea in study participants. | Number of participants with abnormal findings in serum urea will be reported. | 6 months | 
| Measurement of serum Creatinine in study participants. | Number of participants with abnormal findings in serum Creatinine will be reported. | 6 months |